Compare Ginkgo Bioworks Holdings Inc (DNA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Weibo Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Weibo Corp trades at $7.84 (market cap $1.88B). The key difference: Weibo Corp is far larger — about 3.2× Ginkgo Bioworks Holdings Inc's market cap, and Weibo Corp pays a 7.96% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | WB | |
|---|---|---|
Market Cap | $590.53M | $1.88B |
Sector | Health | Media |
52-Week High | $16.14 | $12.83 |
52-Week Low | $5.48 | $7.20 |
Enterprise Value | $627.78M | $1.16B |
Dividend Yield | — | 7.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Weibo (WB) trades at $7.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong valuation metrics including a P/E of 5.37 and P/B of 0.49. The company reported $449.02M net income for 2025 with a 25.55% margin, though recent quarters saw EPS misses. A $0.61 dividend for H1-26 is scheduled, and cash flow trends show improvement in 2025. Analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. Upside is supported by low multiples and robust cash flow, but risks include user engagement challenges from rivals like Douyin and inconsistent earnings performance. The stock presents a value opportunity with income, yet requires monitoring of competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
